URGENT: DRUG RECALL

December 3, 2015

Re: Ventolin® HFA Metered Dose Inhalers

Dear Valued Customer:

GlaxoSmithKline is recalling the Ventolin® HFA Inhaler lots listed below from the wholesale and retail levels only. These lots are being recalled due to the potential that a low level of canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf-life.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC</th>
<th>Lot Number</th>
<th>Expiry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventolin® HFA Inhaler – 200 Actuations</td>
<td>0173-0682-20</td>
<td>5ZP1708</td>
<td>December 2016</td>
</tr>
<tr>
<td>Ventolin® HFA Inhaler – 200 Actuations</td>
<td>0173-0682-20</td>
<td>5ZP1951</td>
<td>February 2017</td>
</tr>
</tbody>
</table>

Recalled product was shipped between September 30, 2015 and October 8, 2015.

Stop distributing and immediately quarantine only the lots listed above. Please carry out a physical count and record this data on the Business Reply Card and the Packing Slip which are included with this letter. Please examine your inventory immediately and return all units of only the lots listed along with the Packing Slip using the enclosed UPS Return Label to:

GlaxoSmithKline, c/o Stericycle
2670 Executive Drive, Suite A
Indianapolis, IN  46241

It is very important that you provide the requested information on the enclosed postage paid Business Reply Card and return it to us within five (5) business days, even if you do not have the listed lots of Ventolin® HFA in stock.

Thank you for your cooperation. For shipping assistance or questions about the recall process, please contact Stericycle at 1-888-628-0731. Reimbursement will be issued at the price in effect as of the date of this recall announcement. In addition, reimbursement will also include a service and handling payment only. Stericycle is actively notifying customer accounts. Credit or reimbursement for any additional notifications to dispensing entities will not be provided.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

We appreciate your immediate attention and cooperation. GlaxoSmithKline remains committed to product quality, integrity, and patient satisfaction and we sincerely regret any inconvenience this action may cause.

Enclosures:  Postage Paid Business Reply Card
            Packing Slip and Prepaid UPS Return Service Shipping Label